Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT-3921 in HTLV-1-Associated Myelopathy
NCT05240612Phase 1Completed
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- May 2022
- Primary completion
- Sep 2023
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in HTLV-1-associated myelopathy (HAM) comparing MT-3921 with Placebo (2 arms). Primary endpoints: Percentage of subjects with adverse events at 36 weeks, Percentage of subjects with adverse reactions at 36 weeks and 2 more. Started May 2022; status: completed.
02
Drugs
unasnemab
03
Conditions
HTLV-1-associated myelopathy (HAM)
Beyond the preview
Go deeper on NCT05240612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05240612.